Trials / Completed
CompletedNCT01122667
Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)
A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the Area Under the Curve (AUC(0 to infinity)) of anacetrapib in subjects with impaired renal function and healthy matched control subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | anacetrapib | single dose administration of anacetrapib (MK0859) 100 mg oral tablet |
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2011-06-01
- Completion
- 2011-06-01
- First posted
- 2010-05-13
- Last updated
- 2015-08-14
Source: ClinicalTrials.gov record NCT01122667. Inclusion in this directory is not an endorsement.